HomeREGULATORY
REGULATORY

Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
(Aug.24.2017)

Chuikyo General Meeting on Aug. 23
Kowa took a pass on the reimbursement listing in August of its hoped-to-be big-seller hyperlipidemia drug Parmodia (pemafibrate) as it failed to reach an agreement with regulators on its pricing, a spokesperson said on August 23. This means its launch will be pushed back by at least three months, with the next round of new drug listing slated for November ...
(LOG IN FOR FULL STORY)

News Calendar